Navigation Links
Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
Date:6/16/2008

HAYWARD, Calif., June 16 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has completed enrollment in a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high cholesterol and triglycerides.

The randomized, double-blind study is designed to assess the drug's effect on dyslipidemia and insulin resistance, and will evaluate two different doses of MBX-8025 given over an 8-week period, both alone and in combination with Lipitor(R) (atorvastatin). The primary endpoint is the reduction in Apo B-100, the atherogenic lipoprotein in LDL (low-density lipoprotein), compared to placebo. Secondary endpoints include measurements of the effect of treatment on LDL, HDL (high-density lipoprotein), triglycerides and body weight and composition. Metabolic parameters, including glucose and insulin levels and insulin sensitivity, are also being assessed.

"America is suffering from an epidemic of obesity and its consequences, one of which is mixed dyslipidemia. Patients with this type of dyslipidemia have elevated LDL cholesterol, but also have elevated triglycerides, low HDL levels, and have a large amount of small, dense LDL particles, which are much more atherogenic," said David B. Karpf, M.D., the chief medical officer of Metabolex. "Statins do a good job of lowering LDL, but are not fully effective because they do not treat the other aspects of mixed dyslipidemia. This enrollment milestone puts us one step closer to understanding the ability of MBX-8025 to treat mixed dyslipidemia, as well as providing preliminary evidence of the drug's ability to enhance insulin sensitivity and reduce body weight -- two additional features of metabolic syndrome."

About Dyslipidemia

A growing body of research indicates that cardiac risk is affected by a number of different compounds in the blood,
'/>"/>

SOURCE Metabolex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Metabolex Initiates Phase 1 Trial of MBX-2982
2. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
3. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
4. Pharmaxis Long-Term Safety Study of Bronchitol Completes
5. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
6. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
7. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
8. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
9. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
10. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
11. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 ... plc (NASDAQ: ENDP ) (TSX: ENL), and ... announced today that they have submitted a New Drug ... U.S. Food and Drug Administration (FDA).  Buprenorphine HCl Buccal ... severe enough to require daily, around-the-clock, long-term opioid treatment ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... the "US Self-monitoring Blood Glucose Market" report ... This market insight focuses on the ... the United States . Reimbursement analysis and ... product analyses for more than 73 SMBG meters have ...
(Date:12/22/2014)... CHESTERBROOK, Pa. and STOCKHOLM ... AB (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today ... Use (CHMP) of the European Medicines Agency (EMA) has ... (collagenase clostridium histolyticum) for the treatment of adult men ... deformity of at least 30 degrees at the start ...
Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... Medical Alarm Concepts Holding, Inc. (OTCQB: MDHI.PK), today provided ... merger with Carrollton, Texas-based FirstFitness Nutrition Inc., a leading ... products.  On November 9th, 2011, Medical Alarm Concepts announced ... its plan to merge the financials and operations of ...
... human papillomavirus vaccine that is now recommended for male ... autoimmune conditions such as lupus, rheumatoid arthritis, type 1 ... according to a new study in the Journal ... used electronic health records to conduct an observational safety ...
Cached Medicine Technology:MDHI Provides Update on FirstFitness Merger - Operation Expected to Produce 2012 Revenues in Excess of $12 Mil - Warrants of 15.5 Mil Cancelled 2MDHI Provides Update on FirstFitness Merger - Operation Expected to Produce 2012 Revenues in Excess of $12 Mil - Warrants of 15.5 Mil Cancelled 3MDHI Provides Update on FirstFitness Merger - Operation Expected to Produce 2012 Revenues in Excess of $12 Mil - Warrants of 15.5 Mil Cancelled 4MDHI Provides Update on FirstFitness Merger - Operation Expected to Produce 2012 Revenues in Excess of $12 Mil - Warrants of 15.5 Mil Cancelled 5Kaiser Permanente Study Finds Gardasil Does Not Trigger Lupus, Rheumatoid Arthritis or Type 1 Diabetes After Vaccination 2Kaiser Permanente Study Finds Gardasil Does Not Trigger Lupus, Rheumatoid Arthritis or Type 1 Diabetes After Vaccination 3Kaiser Permanente Study Finds Gardasil Does Not Trigger Lupus, Rheumatoid Arthritis or Type 1 Diabetes After Vaccination 4
(Date:12/24/2014)... December 24, 2014 For nearly 20 ... housewarmings, new babies, graces, and all of life's rites ... and author, Nancy Tupper Ling, in Toasts: The ... Viva Editions. , Organized by category and containing ... won't appear anywhere else, this timely tome contains sayings ...
(Date:12/24/2014)... As 2014 draws to a close, ... investing time and money into a new or tankless ... specializes in tankless and eco-friendly products or service. Greenstar ... heater in 2015 to research “green” and environmentally friendly ... Home Services specializes in eco-friendly and environmentally conscious ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, ... might hurt your child in the classroom, a new study ... grade lagged behind by eighth grade, said researchers who reviewed ... "The largest effects were found for the kids who ... Purtell, assistant professor of human sciences at Ohio State University. ...
(Date:12/24/2014)... (HealthDay News) -- Long-term fear of terrorists may damage your ... new study from Israel suggests. , , Conducted by researchers ... Israelis. In Israel, the threat of war and terrorism has ... "We wanted to test whether fear of terrorism can ... death," study author Hermona Soreq, a professor of molecular neuroscience, ...
(Date:12/22/2014)... B. E. Smith, the only full-service leadership ... retained to lead a national chief compliance officer ... Oceanside, Calif. The top executive search firm ... placed more than 900 healthcare executives into organizations. ... Gold Seal-approved, full-service acute-care hospital serving San Diego County’s ...
Breaking Medicine News(10 mins):Health News:Greenstar Home Services Offers Tankless Water Heater Advice to Local Homeowners 2Health News:Can Fast Food Hinder Learning in Kids? 2Health News:Terrorism Fears May Shorten Your Life, Study Finds 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 3
... published in volume 14 issue 6 of World ... presented to Dr Cosimo Sperti of University of ... laparotomy performed in another hospital for an unresectable ... vein. Total pancreatectomy together with resection and reconstruction ...
... Ph.D., MBA, RN is vice president of research,and ... announced it,has appointed Joann Genovich-Richards, Ph.D., MBA, RN, ... research and measurement. The,position will support the development ... analyze existing data from accredited companies and,other sources ...
... March 13 inVentiv Clinical,Solutions, LLC (inVentiv Clinical), ... that they will establish operations in Latin,America, a ... will be,based in Sao Paulo, Brazil, with the ... inVentiv Clinical,s Latin American operations,will be led by ...
... TOC ; TSX: TOC) has been selected by ... care hospitals in high-growth urban and,suburban markets, to complete ... care hospitals., Like other health systems in the ... a limited field of candidates.,Thomson Healthcare, using its Market ...
... Ohio, March 13 Cardinal Health, a,global ... the safety and,productivity of health care, today ... Kaufmann as group president of its Healthcare ... role, Kaufmann, 45, will be responsible for ...
... the Future, JACKSON, Miss., March 13 ... technology partner, announces Christwood Retirement,Community in Covington, ... Study,(OBS) partner site for SamarionSolution(SM), the nursing ... Christwood, which recently celebrated a decade as ...
Cached Medicine News:Health News:URAC Announces New Leadership to Mine Health Care Management Data and Develop Measurement Programs 2Health News:URAC Announces New Leadership to Mine Health Care Management Data and Develop Measurement Programs 3Health News:inVentiv Clinical Expands Operations to Emerging Latin American Region 2Health News:inVentiv Clinical Expands Operations to Emerging Latin American Region 3Health News:Thomson Healthcare Undertakes Medical Staff Development Project for IASIS Healthcare 2Health News:Thomson Healthcare Undertakes Medical Staff Development Project for IASIS Healthcare 3Health News:Cardinal Health Names Michael C. Kaufmann to Lead Pharmaceutical Segment 2Health News:Samarion(SM) Announces Second Outcome Based Study Partner Site for LTC Industry's Only Enterprise Quality Improvement System 2Health News:Samarion(SM) Announces Second Outcome Based Study Partner Site for LTC Industry's Only Enterprise Quality Improvement System 3
... For use in the percutaneous retrieval of indwelling ... wire guides, and other foreign objects. A ... around the lead body. It is delivered to ... flexible 12 Fr cannula that is placed coaxially ...
... Novalis, BrainLAB's dedicated ... radiosurgery and radiotherapy (SRS/SRT), ... highly precise treatments of ... head & neck tumors, ...
The Radionics XKnife RT2 system provides a precise and versatile stereotactic radiation therapy solution....
Clinac EX Platinum accelerators offer all the high performance features of the EX series and come with the latest high-precision dose sculpting technology for advanced tumor control....
Medicine Products: